Jacobs Levy Equity Management, Inc Cti Biopharma Corp Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$1.72 - $5.24 $317,725 - $967,953	-184,724 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.81 - $5.26 $563,514 - $777,975	147,904 Added 401.69%	184,724 $920,000
Q1 2018 May 15, 2018	SELL	$2.7 - $4.06 $135,075 - $203,113	-50,028 Reduced 57.6%	36,820 $144,000
Q4 2017 Feb 13, 2018	BUY	$2.47 - $3.34 $40,330 - $54,535	16,328 Added 23.15%	86,848 $233,000
Q3 2017 Nov 14, 2017	BUY	$3.12 - $3.65 $83,616 - $97,820	26,800 Added 61.3%	70,520 $225,000
Q2 2017 Nov 09, 2017	BUY	N/A	43,720	43,720 $145,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.